CYP1A2, CYP2A6, CYP2B6, CYP3A4 and CYP3A5 Polymorphisms in Two Bantu-Speaking Populations from Cameroon and South Africa: Implications for Global Pharmacogenetics

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 10, Iss. 1, 2012-03 ,pp. : 43-53

Bentham Science Publishers

Access to resources Recommend Favorite

Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms

By Gunes Arzu   Dahl Marja-Liisa  

Pharmacogenomics, Vol. 9, Iss. 5, 2008-05 ,pp. : 625-637

Future Medicine

Access to resources Recommend Favorite

Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives

By Hisamuddin Irfan M   Yang Vincent W  

Pharmacogenomics, Vol. 8, Iss. 6, 2007-06 ,pp. : 635-643

Future Medicine

Access to resources Recommend Favorite

Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population

By Du Jing   Xing Qinghe   Xu Lingyun   Xu Mingsheng   Shu Anli   Shi Yongyong   Yu Lan   Zhang Aiping   Wang Lei   Wang Hongsheng   Li Xingwang   Feng Guoyin   He Lin  

Pharmacogenomics, Vol. 7, Iss. 6, 2006-09 ,pp. : 831-841

Future Medicine

Access to resources Recommend Favorite

Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests

By Lee Su-Jun   Goldstein Joyce A  

Pharmacogenomics, Vol. 6, Iss. 4, 2005-06 ,pp. : 357-371

Future Medicine

Access to resources Recommend Favorite